Drug Detail

Information about Ziftomenib

Generic Name	Ziftomenib
IND	KO-539
Brand Name (US)
Manufacturer	Kura Oncology Inc
Drug Type
Delivery	Oral
Approval Status	Phase 1/2
Indications	AML GIST
Overall Strategy	Synthetic lethality via KIT when combined with a KIT inhibitor
Strategy	Reduce menin-MLL epigenetic upregulatiion of KIT transcription
Drug Category	Menin inhibitor

Possible mechanism of action. Imatinib causes vulnerability that can be targeted by ziftomenib at the transcriptional and/or protein stability levels, creating synthetic lethality.